{"url_path":"/sec/zyme/8-k/2026-06-29/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-29","source_url":"https://www.sec.gov/Archives/edgar/data/1937653/0001193125-26-286829-index.html","accession_number":"0001193125-26-286829","cik":"0001937653","ticker":"ZYME","issuer_name":"Zymeworks Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1937653/0001193125-26-286829-index.html","primary_entity_key":"0001937653","primary_entity_name":"Zymeworks Inc."},"word_count":180,"has_tables":true,"body_markdown":"Item 9.01 – Financial Statements and Exhibits\n\n(d) The following exhibits are being filed herewith:\n\n \n\nExhibit No.\n\n  \n\nDescription\n\n2.1*\n  \n[Agreement and Plan of Merger, dated as of June 28, 2026, by and among Zymeworks Inc., Zymeworks Merger Sub 1, and Theravance Biopharma, Inc.](d156494dex21.htm)\n\n10.1\n  \n[Form of Contingent Value Rights Agreement.](d156494dex101.htm)\n\n99.1\n  \n[Press Release, dated June 29, 2026.](d156494dex991.htm)\n\n99.2\n  \n[Investor Webcast Presentation, dated June 29, 2026.](d156494dex992.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n*\n\nSchedules omitted pursuant to Item 601(b)(2) of Regulation S-K. Parent agrees to furnish supplementally a copy of any omitted schedule to the SEC upon request; provided, however, that Parent may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any schedules or exhibits so furnished.\n\n \n\n5\n\nSIGNATURE\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.\n\n \n\n \n \n \n \nZymeworks Inc.\n\n \n\n \n(registrant)\n\nDate: June 29, 2026\n \n\n \nBy:\n \n\n/s/ Kenneth Galbraith\n\n \n\n \nName:\n \nKenneth Galbraith\n\n \n\n \nTitle:\n \nChair, President and Chief Executive Officer"}